Galectin Therapeutics Inc. 2023 Form 10-K Summary
Business context and reporting period
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company developing galectin-targeting therapies for fibrotic disease and cancer. The filing covers the fiscal year ended December 31, 2023; it is an annual filing rather than a quarterly report for 2023 Q4. The lead candidate is belapectin (GR-MD-02), an intravenous galectin-3 inhibitor being evaluated primarily for prevention of esophageal varices in patients with NASH cirrhosis and portal hypertension.
- NAVIGATE Phase 2b/3 trial: 357 patients randomized by February 2023 across more than 150 sites in 14 countries.
- An interim efficacy and safety analysis is expected in the fourth quarter of 2024.
- The company has no approved products and has generated no revenue since inception.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $32.1 million | $31.7 million | +$0.4 million, 1% |
| General and administrative expense | $5.9 million | $6.6 million | -$0.7 million, 10% |
| Total operating expenses | $38.1 million | $38.4 million | -$0.3 million |
| Operating loss | $38.1 million | $38.4 million | Improved by $0.3 million |
| Net loss | $41.1 million | $38.8 million | Worsened by $2.3 million |
| Net loss applicable to common stockholders | $44.8 million | $38.9 million | Worsened by $5.9 million |
| Basic and diluted loss per share | $0.74 | $0.65 | Worsened by $0.09 |
| Net cash used in operations | $33.0 million | $31.1 million | Increased by $1.9 million |
| Cash and cash equivalents at year-end | $25.7 million | $18.6 million | +$7.1 million |
Clinical-program spending declined to $23.9 million from $26.7 million, primarily because of lower NAVIGATE-related and belapectin manufacturing costs. Preclinical spending increased to $3.0 million from $1.3 million, while research and development payroll and other costs increased to $5.2 million from $3.7 million. General and administrative expense declined primarily because of lower stock-based compensation.
The company reported total liabilities of $88.4 million and stockholders’ deficit of $62.0 million at December 31, 2023. Accumulated deficit was $354.4 million. The filing does not present meaningful margin metrics because the company has no revenue; operating and net margins are therefore not meaningful.
Debt, financing and capital structure
- Convertible notes payable to Chairman Richard E. Uihlein had a carrying value of $30.9 million at year-end, representing three $10 million notes maturing in 2025 unless converted.
- The company drew $30.0 million under a related-party convertible line of credit during 2023. The line had $20.0 million available at December 31, 2023, subject to its terms.
- Interest expense increased to $2.8 million from $1.0 million, reflecting the larger debt balance, debt discounts and related financing costs.
- The company issued $10.0 million of common stock upon exercise of warrants in 2023.
- Outstanding warrants totaled 9.3 million at year-end, with a weighted-average exercise price of $4.22; outstanding options totaled 6.3 million, with a weighted-average exercise price of $2.66.
- Potential dilution from warrants, options, convertible debt, the convertible line of credit and preferred stock totaled approximately 36.3 million shares excluded from diluted loss per share because the securities were anti-dilutive.
Material changes versus the prior comparable period
- Cash increased despite higher operating cash use because the company raised $40.0 million through related-party debt and warrant exercises, compared with $10.0 million of financing proceeds in 2022.
- Net loss increased primarily because of higher interest expense, derivative fair-value expense and a $3.6 million non-cash deemed dividend related to modification of 10X Fund warrants.
- Common shares outstanding increased to 61.9 million at December 31, 2023 from 59.4 million at December 31, 2022.
- Research and development expense was broadly stable, but spending shifted from clinical programs toward preclinical support, manufacturing and personnel-related activities.
- The 2019 Omnibus Equity Incentive Plan was increased to authorize 10.0 million shares; 3.95 million shares remained available for future grants at year-end.
Outlook, commentary, risks and unusual items
Management expects current cash and available financing to fund currently planned operations at least through March 31, 2025. The company expects to require additional capital thereafter and intends to pursue debt, equity, collaboration, partnership or other strategic financing. There is no assurance that financing will be available on acceptable terms or at all.
On March 29, 2024, after year-end, the company entered into a supplemental unsecured convertible line of credit with Mr. Uihlein for up to $10.0 million, drawable through March 31, 2025. Advances bear interest at the applicable federal rate plus 2%, are due by March 31, 2026, may be converted at the lender’s option subject to a $3.00 minimum conversion price, and may result in warrants for up to 200,000 shares.
- NAVIGATE results remain the principal near-term clinical catalyst. The trial could be modified, expanded, stopped for efficacy or stopped for futility based on the interim analysis.
- Belapectin has not received FDA approval, and prior NASH-CX and NASH-FX studies did not meet their primary endpoints, although the company reported favorable findings in selected subgroups.
- The proposed Phase 2 oncology trial in recurrent or metastatic head and neck cancer depends on financing and has not commenced.
- The company relies on third-party clinical research organizations, sites and manufacturers, with no long-term supplier agreements and potential exposure to supply-chain delays.
- Clinical development, regulatory approval, manufacturing, patient enrollment, competition, intellectual property, cybersecurity, litigation and future financing remain significant risks.
- The audit report expressed an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the external auditor was not engaged to provide an opinion on internal control effectiveness because the company is a smaller reporting company.
- No material pending legal proceedings were reported, and the company reported no cybersecurity incidents with a material impact.
Most important facts for investors to verify
- Timing, design and statistical outcome of the NAVIGATE interim analysis expected in the fourth quarter of 2024.
- Available cash, remaining borrowing capacity, debt maturities and the terms and utilization of the March 2024 supplemental credit facility.
- Potential dilution from approximately $30 million of convertible notes, the convertible line of credit, 9.3 million warrants, 6.3 million options and preferred-stock conversion rights.
- Whether additional financing can be obtained before the company’s projected liquidity runway ends and on what terms.
- Clinical-trial accruals and other obligations, including approximately $8.0 million of accrued clinical-trial expenses within total accrued expenses of $9.2 million at year-end.
- Regulatory and commercial prospects for belapectin, given the absence of revenue, product approvals and a history of losses.